-- 根据周四提交给澳大利亚证券交易所的文件，Articore集团（ASX：ATG）公布其第三财季毛利润为3280万澳元，较去年同期的3220万澳元增长1.6%。 截至3月31日的季度，付费获客后的毛利润（GPAPA）同比下降3.4%至1950万澳元，而去年同期为2020万澳元。GPAPA利润率接近31%，较去年同期增长160个基点。 截至3月31日的季度，市场平台收入同比下降8.5%至6320万澳元，而去年同期为6900万澳元。 该公司重申了其财年展望，预计GPAPA利润率为27%至29%，息税前利润在600万澳元至1000万澳元之间。预计本财年基本现金流将达到800万澳元至1200万澳元。 该公司股价在上周四的交易中上涨了2%。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661